Patients treated with Xenon Pharmaceuticals’ investigational potassium channel opener XEN1101 experienced a significant and dose-dependent reduction in seizure frequency.
Tag Archive for: Phase IIb trial
Belgium-based BioSenic is suspending the development of ALLOB, an investigational allogeneic cell therapy derived from mesenchymal stem cells, which was being assessed as a treatment for tibial fractures, the company announced Monday.
Novartis is cleaning house, cutting its Huntington’s disease program along with several others. The company announced multiple program stops and delays in its full-year 2022 report Wednesday.
California-based Vera Therapeutics unveiled results Tuesday from the Phase IIb ORIGIN trial showing its immunoglobulin A nephropathy (IgAN) candidate atacicept met the primary endpoint of reduced proteinuria.
Nimbus Therapeutics reported positive Phase IIb results on Wednesday for its TYK2 inhibitor, NDI-034858, in moderate-to-severe plaque psoriasis.
Virios Therapeutics announced Monday its lead asset IMC-1 fell short of its primary endpoint in the Phase IIb FORTRESS study in patients with fibromyalgia.
RhoVac AB announced Tuesday that the company’s prostate cancer drug candidate failed to meet targets in a Phase IIb study.
